Review



anti eef2  (Danaher Inc)


Bioz Verified Symbol Danaher Inc is a verified supplier
Bioz Manufacturer Symbol Danaher Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    Danaher Inc anti eef2
    Anti Eef2, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 356 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ab91335/Anti-EGFR+(phospho+Y1068)+antibody/pm28386023-223-72-75
    Average 99 stars, based on 356 article reviews
    anti eef2 - by Bioz Stars, 2026-09
    99/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: BMP4 upregulates glycogen synthesis through the SMAD/SLC2A1 (GLUT1) signaling axis in hepatocellular carcinoma (HCC) cells
    Article Snippet: .. The proteins of interest were assessed by being incubated with the following primary antibodies at 4 °C overnight: anti-GYS1(1:500; Abcam; Catab40810), anti-BMP4 (1:1000; Bimake; Cat# A5543), anti-SLC2A1 (1:1000; Proteintech; Cat# 21829-1-AP), anti-SMAD5 (1:1000, Bimake; Cat# A5511), anti-p-SMAD5 (1:1000; Abcam; Cat# ab92698), and anti-β-Actin (1:2000, Proteintech; Cat# 60008-1-Ig). ..

    Article Title: Immuno-PET Detects Antibody-Drug Potency on Coadministration with Statins.
    Article Snippet: The membranes were incubated in 5% (m/v) milk (Bio-Rad) or bovine serum albumin (Sigma) in tris-buffered saline buffer-polysorbate (EZ BioResearch). .. The membranes were then incubated with the primary antibodies: mouse antib-actin, 1:10,000 (A1978; Sigma); rabbit anti-HER2, 1:800 (ab131490; Abcam); rabbit anti-HER2 phospho Y1139, 1:500 (ab53290; Abcam); rabbit anti–epidermal growth factor receptor (EGFR), 1:1,000 (ab52894; Abcam); rabbit anti-EGFR phospho Y1068, 1:500 (ab40815; Abcam); rabbit anti-HER3, 1:500 (ab32121; Abcam); rabbit anti-HER3 phospho Y1289, 1:2,500 (ab76469; Abcam); mouse antiphosphotyrosine, 1:2,000 (05-321; Sigma); rabbit anti–poly(adenosine diphosphate ribose) polymerase (PARP), 1:1,000 (9542; Cell Signaling Technology); rabbit anti– histone H2A.X, 1:1,000 (2595; Cell Signaling Technology); or rabbit anti–phosphohistone H2A.X (Ser139), 1:1,000 (9718; Cell Signaling Technology). .. After washing of the membranes with tris-buffered saline buffer-polysorbate, the membranes were incubated with the secondary antibody goat anti-rabbit IgG (heavy- and light-chain) conjugated with AlexaFluor Plus 680 (Invitrogen) or goat anti-mouse IgG (heavy- and light-chain) conjugated with AlexaFluor Plus 800 (Invitrogen).

    Article Title: Clinicopathologic Dissociation: Robust Lafora Body Accumulation in Malin KO Mice Without Observable Changes in Home-cage Behavior
    Article Snippet: For co-immunostaining, paraffin-embedded brain sections were deparaffinized and rehydrated by processing with xylene, decreasing concentrations of ethanol in water, and subjected to antigen retrieval using citrate buffer pH6.0 (C9999, Sigma-Aldrich). .. Sections were blocked with 5% normal donkey serum (in 0.1% Triton X-100, PBS) for 1 h and incubated for 48 h at 4°C with primary antibodies diluted in blocking solution, including those targeted against glycogen synthase 1 (Gys1, rabbit, 1:400, ab40810, Abcam), glial fibrillary acidic protein (GFAP, mouse, 1:500, BD556330, BD bioscience) and ionized calcium binding adaptor protein 1 (Iba1, goat, 1:350, ab5076, Abcam). .. Sections were then washed with PBS and incubated at room temperature for 2 h with secondary antibodies (ThermoFisher Scientific) diluted in blocking buffer: Alexa Fluor 488 donkey anti-mouse IgG (H+L) (1:500, Invitrogen A-21202), Alexa Fluor 488 donkey anti-goat IgG (H+L) (1:500, Invitrogen A-11055) and Alexa Fluor 594 donkey anti-rabbit IgG (H+L) (1:500, Invitrogen A-21207).

    Article Title: Epigenetic deregulation of MLF1 drives intrahepatic cholangiocarcinoma progression through EGFR/AKT and Wnt/β-catenin signaling
    Article Snippet: .. After blocking, the membranes were incubated first with anti-MLF1 (1:500, Santa Cruz, sc-514294), anti–DNA methyltransferase (DNMT)1 (1:500, Santa Cruz, sc-271729), anti-DNMT3A (1:1000, Santa Cruz, sc-365769), anti-DNMT3B (1:1000, Santa Cruz, sc-376043), anti-AKT (1:1000, CST, #4691), anti-phospho-AKT(Ser473, 1:1000, CST, #4060), anti-β-catenin (1:1000, CST, #8480), anti-phospho-β-catenin (Ser675, 1:1000, CST, #4176), anti-E-cadherin (1:1000, CST, #3195), anti-N-cadherin (1:1000, CST, #13116), anti-vimentin (1:1000, Abcam, ab92547), anti-LRP6 (1:1000, CST, #3395), anti-phospho-LRP6 (Ser1490, 1:1000, CST, #2568), anti-Bcl2 (1:1000, Abcam, ab32124), anti-Bcl-XL (1:1000, Abcam, ab32370), anti-EGFR (1:3000, Abcam, ab52894), anti-phospho-EGFR (Y1068, 1:3000, Abcam, ab40815), anti-phospho-EGFR (S1046 + S1047, 1:500000, Abcam, ab76300), anti-WNT3 (1:500, Santa Cruz, sc-74537), anti-Cleaved Caspase-3 (Asp175, 1:1000, CST, #9664), or anti-CK19 (1:5000, Abcam, ab52625) as described and then incubated with Goat Anti-Rabbit IgG H&L (1:5000, Abcam, ab205718) or m-IgGκ BP-HRP (1:3000, Santa Cruz, sc-516102 ) accordingly. .. Isolation of total RNA from human tissue specimens or cell lines and real-time PCR (RT-PCR) were performed as described., The primer sequences of MLF1, DNMT1, DNMT3A, DNMT3B, DVL1, CSNK1A1, AXIN1/2, FZD1, and β-actin were summarized in Supplemental Table S1, http://links.lww.com/HC9/A392 , which were obtained from GeneChem (Shanghai, China) or SunYa Biotechnology (Hangzhou, China).

    Blocking Assay:

    Article Title: Clinicopathologic Dissociation: Robust Lafora Body Accumulation in Malin KO Mice Without Observable Changes in Home-cage Behavior
    Article Snippet: For co-immunostaining, paraffin-embedded brain sections were deparaffinized and rehydrated by processing with xylene, decreasing concentrations of ethanol in water, and subjected to antigen retrieval using citrate buffer pH6.0 (C9999, Sigma-Aldrich). .. Sections were blocked with 5% normal donkey serum (in 0.1% Triton X-100, PBS) for 1 h and incubated for 48 h at 4°C with primary antibodies diluted in blocking solution, including those targeted against glycogen synthase 1 (Gys1, rabbit, 1:400, ab40810, Abcam), glial fibrillary acidic protein (GFAP, mouse, 1:500, BD556330, BD bioscience) and ionized calcium binding adaptor protein 1 (Iba1, goat, 1:350, ab5076, Abcam). .. Sections were then washed with PBS and incubated at room temperature for 2 h with secondary antibodies (ThermoFisher Scientific) diluted in blocking buffer: Alexa Fluor 488 donkey anti-mouse IgG (H+L) (1:500, Invitrogen A-21202), Alexa Fluor 488 donkey anti-goat IgG (H+L) (1:500, Invitrogen A-11055) and Alexa Fluor 594 donkey anti-rabbit IgG (H+L) (1:500, Invitrogen A-21207).

    Article Title: Epigenetic deregulation of MLF1 drives intrahepatic cholangiocarcinoma progression through EGFR/AKT and Wnt/β-catenin signaling
    Article Snippet: .. After blocking, the membranes were incubated first with anti-MLF1 (1:500, Santa Cruz, sc-514294), anti–DNA methyltransferase (DNMT)1 (1:500, Santa Cruz, sc-271729), anti-DNMT3A (1:1000, Santa Cruz, sc-365769), anti-DNMT3B (1:1000, Santa Cruz, sc-376043), anti-AKT (1:1000, CST, #4691), anti-phospho-AKT(Ser473, 1:1000, CST, #4060), anti-β-catenin (1:1000, CST, #8480), anti-phospho-β-catenin (Ser675, 1:1000, CST, #4176), anti-E-cadherin (1:1000, CST, #3195), anti-N-cadherin (1:1000, CST, #13116), anti-vimentin (1:1000, Abcam, ab92547), anti-LRP6 (1:1000, CST, #3395), anti-phospho-LRP6 (Ser1490, 1:1000, CST, #2568), anti-Bcl2 (1:1000, Abcam, ab32124), anti-Bcl-XL (1:1000, Abcam, ab32370), anti-EGFR (1:3000, Abcam, ab52894), anti-phospho-EGFR (Y1068, 1:3000, Abcam, ab40815), anti-phospho-EGFR (S1046 + S1047, 1:500000, Abcam, ab76300), anti-WNT3 (1:500, Santa Cruz, sc-74537), anti-Cleaved Caspase-3 (Asp175, 1:1000, CST, #9664), or anti-CK19 (1:5000, Abcam, ab52625) as described and then incubated with Goat Anti-Rabbit IgG H&L (1:5000, Abcam, ab205718) or m-IgGκ BP-HRP (1:3000, Santa Cruz, sc-516102 ) accordingly. .. Isolation of total RNA from human tissue specimens or cell lines and real-time PCR (RT-PCR) were performed as described., The primer sequences of MLF1, DNMT1, DNMT3A, DNMT3B, DVL1, CSNK1A1, AXIN1/2, FZD1, and β-actin were summarized in Supplemental Table S1, http://links.lww.com/HC9/A392 , which were obtained from GeneChem (Shanghai, China) or SunYa Biotechnology (Hangzhou, China).

    Binding Assay:

    Article Title: Clinicopathologic Dissociation: Robust Lafora Body Accumulation in Malin KO Mice Without Observable Changes in Home-cage Behavior
    Article Snippet: For co-immunostaining, paraffin-embedded brain sections were deparaffinized and rehydrated by processing with xylene, decreasing concentrations of ethanol in water, and subjected to antigen retrieval using citrate buffer pH6.0 (C9999, Sigma-Aldrich). .. Sections were blocked with 5% normal donkey serum (in 0.1% Triton X-100, PBS) for 1 h and incubated for 48 h at 4°C with primary antibodies diluted in blocking solution, including those targeted against glycogen synthase 1 (Gys1, rabbit, 1:400, ab40810, Abcam), glial fibrillary acidic protein (GFAP, mouse, 1:500, BD556330, BD bioscience) and ionized calcium binding adaptor protein 1 (Iba1, goat, 1:350, ab5076, Abcam). .. Sections were then washed with PBS and incubated at room temperature for 2 h with secondary antibodies (ThermoFisher Scientific) diluted in blocking buffer: Alexa Fluor 488 donkey anti-mouse IgG (H+L) (1:500, Invitrogen A-21202), Alexa Fluor 488 donkey anti-goat IgG (H+L) (1:500, Invitrogen A-11055) and Alexa Fluor 594 donkey anti-rabbit IgG (H+L) (1:500, Invitrogen A-21207).

    Membrane:

    Article Title: Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
    Article Snippet: Protein extraction was performed in protein lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40) supplemented with a cocktail of protease and phosphatase inhibitors (cOmplete Mini, Roche; Phosphatase Inhibitor Cocktail 2 and 3, MilliporeSigma). .. A total of 30 μg of protein extracts was separated on NuPAGE 4%–12% BisTris Midi Gels (Invitrogen), transferred to a nitrocellulose blotting membrane (GE Healthcare), and blotted with antibodies against the following: EGFR (Abcam, ab52894), phospho-EGFR (Abcam, ab40815), ERK1 (BD Biosciences — Pharmingen, 554100), ERK2 (BD Biosciences, 610103), phospho-ERK1/2 (Cell Signaling Technology, 9101), AKT (Cell Signaling Technology, 9272), phospho-AKT (Cell Signaling Technology, 9271), MEK1 (Santa Cruz Biotechnology Inc., sc-6250), MEK2 (BD Biosciences, 610235), phospho-MEK1/2 (Cell Signaling Technology, 9154), NF-κB p65 (Santa Cruz Biotechnology Inc., sc-372), phospho–NF-κB p65 (Cell Signaling Technology, 3031), STAT3 (Cell Signaling Technology, 9139), phospho-STAT3 (Cell Signaling Technology, 9131), caspase-3 (Cell Signaling Technology, 9662), cleaved caspase-3 (Cell Signaling Technology, 9661), pan-RAS (Calbiochem, OP40), BIRC5 (Cell Signaling Technology, 2808), Lamin B (Santa Cruz Biotechnology Inc., sc-6216), HA.11 (BioLegend, 901513), GAPDH (MilliporeSigma, G8795), and Vinculin (MilliporeSigma, V9131). ..



    Similar Products

    99
    Danaher Inc phalloidin ifluor 488 reagent
    Phalloidin Ifluor 488 Reagent, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ab91335/Phalloidin-iFluor+555+Reagent%2C+300+tests/bio_rxiv__2023__09__08__556827-184-49-52
    Average 99 stars, based on 1 article reviews
    phalloidin ifluor 488 reagent - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    99
    Abcam hoechst 33258

    Hoechst 33258, supplied by Abcam, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ab91335/Cell+Counting+Kit+8+(WST-8+%2F+CCK8)+-+1000test/pmc10484973-24-0-5
    Average 99 stars, based on 1 article reviews
    hoechst 33258 - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    99
    Danaher Inc tgfbr1
    <t>TGFBR1</t> and BMPR2 are the main effector targets of miR-30-3p in HNSCC. ( a ) Predicted interaction between target proteins was analyzed using STRING database. ( b ) Heatmap representing predicted target gene expression was determined by RT-qPCR in HNSCC cell lines ( n = 4–7). ( c ) Western blot analysis of CAL27, CAL33, and SCC9 cell lines overexpressing miR-30a-3p or miR-30e-3p (c for miR-ctrl, a for miR-30a-3p and e for miR-30e-3p, n = 3–12, * p < 0.05, ** p < 0.01 and *** p < 0.001). ( d ) Immunofluorescence analysis by confocal microscopy of HNSCC cell lines overexpressing miR-30a-3p or miR-30e-3p ( n = 3–4). ( e ) Predicted pairing region between miR-30a-3p or miR-30e-3p and TGFBR1 (position 812–818) and BMPR2 (position 1411–1417). ( f ) Evasion of CAL27, CAL33, and SCC9 cell lines with TGF-β or BMP inhibitors ( n = 16–49 spheroids, * p < 0.05, ** p < 0.01 and *** p < 0.001). ( g ) Survival fraction of CAL27, CAL33, and SCC9 cell lines with TGF-β or BMP inhibitors ( n = 9–12, * p < 0.05 and *** p < 0.001).
    Tgfbr1, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ab91335/Rhodamine+Phalloidin+Reagent+300+test/pmc10342301-208-18-21
    Average 99 stars, based on 1 article reviews
    tgfbr1 - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    94
    Danaher Inc cd14
    <t>TGFBR1</t> and BMPR2 are the main effector targets of miR-30-3p in HNSCC. ( a ) Predicted interaction between target proteins was analyzed using STRING database. ( b ) Heatmap representing predicted target gene expression was determined by RT-qPCR in HNSCC cell lines ( n = 4–7). ( c ) Western blot analysis of CAL27, CAL33, and SCC9 cell lines overexpressing miR-30a-3p or miR-30e-3p (c for miR-ctrl, a for miR-30a-3p and e for miR-30e-3p, n = 3–12, * p < 0.05, ** p < 0.01 and *** p < 0.001). ( d ) Immunofluorescence analysis by confocal microscopy of HNSCC cell lines overexpressing miR-30a-3p or miR-30e-3p ( n = 3–4). ( e ) Predicted pairing region between miR-30a-3p or miR-30e-3p and TGFBR1 (position 812–818) and BMPR2 (position 1411–1417). ( f ) Evasion of CAL27, CAL33, and SCC9 cell lines with TGF-β or BMP inhibitors ( n = 16–49 spheroids, * p < 0.05, ** p < 0.01 and *** p < 0.001). ( g ) Survival fraction of CAL27, CAL33, and SCC9 cell lines with TGF-β or BMP inhibitors ( n = 9–12, * p < 0.05 and *** p < 0.001).
    Cd14, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ab91335/Human+TNF+alpha+ELISA+Kit/pmc10245533-93-7-8
    Average 94 stars, based on 1 article reviews
    cd14 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    99
    Abcam collagen i
    <t>TGFBR1</t> and BMPR2 are the main effector targets of miR-30-3p in HNSCC. ( a ) Predicted interaction between target proteins was analyzed using STRING database. ( b ) Heatmap representing predicted target gene expression was determined by RT-qPCR in HNSCC cell lines ( n = 4–7). ( c ) Western blot analysis of CAL27, CAL33, and SCC9 cell lines overexpressing miR-30a-3p or miR-30e-3p (c for miR-ctrl, a for miR-30a-3p and e for miR-30e-3p, n = 3–12, * p < 0.05, ** p < 0.01 and *** p < 0.001). ( d ) Immunofluorescence analysis by confocal microscopy of HNSCC cell lines overexpressing miR-30a-3p or miR-30e-3p ( n = 3–4). ( e ) Predicted pairing region between miR-30a-3p or miR-30e-3p and TGFBR1 (position 812–818) and BMPR2 (position 1411–1417). ( f ) Evasion of CAL27, CAL33, and SCC9 cell lines with TGF-β or BMP inhibitors ( n = 16–49 spheroids, * p < 0.05, ** p < 0.01 and *** p < 0.001). ( g ) Survival fraction of CAL27, CAL33, and SCC9 cell lines with TGF-β or BMP inhibitors ( n = 9–12, * p < 0.05 and *** p < 0.001).
    Collagen I, supplied by Abcam, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ab91335/Human+C-Peptide+ELISA+Kit+96+tests/pmc10050374-100-47-51
    Average 99 stars, based on 1 article reviews
    collagen i - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    99
    Abcam ab133195
    <t>TGFBR1</t> and BMPR2 are the main effector targets of miR-30-3p in HNSCC. ( a ) Predicted interaction between target proteins was analyzed using STRING database. ( b ) Heatmap representing predicted target gene expression was determined by RT-qPCR in HNSCC cell lines ( n = 4–7). ( c ) Western blot analysis of CAL27, CAL33, and SCC9 cell lines overexpressing miR-30a-3p or miR-30e-3p (c for miR-ctrl, a for miR-30a-3p and e for miR-30e-3p, n = 3–12, * p < 0.05, ** p < 0.01 and *** p < 0.001). ( d ) Immunofluorescence analysis by confocal microscopy of HNSCC cell lines overexpressing miR-30a-3p or miR-30e-3p ( n = 3–4). ( e ) Predicted pairing region between miR-30a-3p or miR-30e-3p and TGFBR1 (position 812–818) and BMPR2 (position 1411–1417). ( f ) Evasion of CAL27, CAL33, and SCC9 cell lines with TGF-β or BMP inhibitors ( n = 16–49 spheroids, * p < 0.05, ** p < 0.01 and *** p < 0.001). ( g ) Survival fraction of CAL27, CAL33, and SCC9 cell lines with TGF-β or BMP inhibitors ( n = 9–12, * p < 0.05 and *** p < 0.001).
    Ab133195, supplied by Abcam, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ab91335/LDL+Uptake+Assay+Kit+(Cell-Based)+1+Kit/pm36634673-438-58-56
    Average 99 stars, based on 1 article reviews
    ab133195 - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    99
    Abcam pfkfb4 antibody
    (A) Kaplan-Meier survival plots of TNBC breast cancer patients with low or high <t>PFKFB4</t> signature score in TCGA (n = 149) and GEO: GSE21653 (n = 85) database. Medium cut point of PFKFB4 signature score was used to stratified patients. p values were calculated by log rank test. (B) Relative mRNA expression of PFKFB4 in primary tumors and matching metastases in breast cancer patients from GEO: GSE110590 database. p values were calculated by one-way ANOVA and paired t test, two tailed. (C) Immunoblot analyses of PFKFB4 protein expression in LM3.3 human breast cancer cells stably expressing doxycycline inducible non-targeting shRNA (dox-shNT) or two shRNAs targeting PFKFB4 (dox-shPFKFB4 #97 and #99) with or without doxycycline treatment (2 μg/mL). β-actin was used as a loading control. (D) Schematic overview depicting LM3.3 spontaneous metastatic breast cancer model with doxycycline treatment schedule (n = 10). (E) The weight of resected primary tumors (n = 10). Error bars are presented as mean ± SD. ns, not significant, calculated by one-way ANOVA with Dunnett’s multiple comparisons test. (F) Immunoblot analyses of PFKFB4 expression in surgically resected LM3.3 primary tumors after 7 days of doxycycline treatment. Three animal bearing tumors (n = 3) from each group were used for analysis. (G) Representative IVIS image of systemic metastases from each group at day 26 after primary tumor implantation. (H) The kinetics of systemic metastases development after primary tumors were resected, as measured by IVIS imaging (n = 10). Error bars are presented as mean ± SEM. ***p < 0.001 by two-way ANOVA with Dunnett’s multiple comparisons test. See also .
    Pfkfb4 Antibody, supplied by Abcam, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ab91335/Anti-Tyrosine+Hydroxylase+antibody/pmc09807018-306-0-2
    Average 99 stars, based on 1 article reviews
    pfkfb4 antibody - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    c myc  (Abcam)
    99
    Abcam c myc
    (A) Kaplan-Meier survival plots of TNBC breast cancer patients with low or high <t>PFKFB4</t> signature score in TCGA (n = 149) and GEO: GSE21653 (n = 85) database. Medium cut point of PFKFB4 signature score was used to stratified patients. p values were calculated by log rank test. (B) Relative mRNA expression of PFKFB4 in primary tumors and matching metastases in breast cancer patients from GEO: GSE110590 database. p values were calculated by one-way ANOVA and paired t test, two tailed. (C) Immunoblot analyses of PFKFB4 protein expression in LM3.3 human breast cancer cells stably expressing doxycycline inducible non-targeting shRNA (dox-shNT) or two shRNAs targeting PFKFB4 (dox-shPFKFB4 #97 and #99) with or without doxycycline treatment (2 μg/mL). β-actin was used as a loading control. (D) Schematic overview depicting LM3.3 spontaneous metastatic breast cancer model with doxycycline treatment schedule (n = 10). (E) The weight of resected primary tumors (n = 10). Error bars are presented as mean ± SD. ns, not significant, calculated by one-way ANOVA with Dunnett’s multiple comparisons test. (F) Immunoblot analyses of PFKFB4 expression in surgically resected LM3.3 primary tumors after 7 days of doxycycline treatment. Three animal bearing tumors (n = 3) from each group were used for analysis. (G) Representative IVIS image of systemic metastases from each group at day 26 after primary tumor implantation. (H) The kinetics of systemic metastases development after primary tumors were resected, as measured by IVIS imaging (n = 10). Error bars are presented as mean ± SEM. ***p < 0.001 by two-way ANOVA with Dunnett’s multiple comparisons test. See also .
    C Myc, supplied by Abcam, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ab91335/Recombinant+Anti-EGFR+antibody/pmc04106866-197-35-36
    Average 99 stars, based on 1 article reviews
    c myc - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    99
    Abcam peptide ab190844
    (A) Kaplan-Meier survival plots of TNBC breast cancer patients with low or high <t>PFKFB4</t> signature score in TCGA (n = 149) and GEO: GSE21653 (n = 85) database. Medium cut point of PFKFB4 signature score was used to stratified patients. p values were calculated by log rank test. (B) Relative mRNA expression of PFKFB4 in primary tumors and matching metastases in breast cancer patients from GEO: GSE110590 database. p values were calculated by one-way ANOVA and paired t test, two tailed. (C) Immunoblot analyses of PFKFB4 protein expression in LM3.3 human breast cancer cells stably expressing doxycycline inducible non-targeting shRNA (dox-shNT) or two shRNAs targeting PFKFB4 (dox-shPFKFB4 #97 and #99) with or without doxycycline treatment (2 μg/mL). β-actin was used as a loading control. (D) Schematic overview depicting LM3.3 spontaneous metastatic breast cancer model with doxycycline treatment schedule (n = 10). (E) The weight of resected primary tumors (n = 10). Error bars are presented as mean ± SD. ns, not significant, calculated by one-way ANOVA with Dunnett’s multiple comparisons test. (F) Immunoblot analyses of PFKFB4 expression in surgically resected LM3.3 primary tumors after 7 days of doxycycline treatment. Three animal bearing tumors (n = 3) from each group were used for analysis. (G) Representative IVIS image of systemic metastases from each group at day 26 after primary tumor implantation. (H) The kinetics of systemic metastases development after primary tumors were resected, as measured by IVIS imaging (n = 10). Error bars are presented as mean ± SEM. ***p < 0.001 by two-way ANOVA with Dunnett’s multiple comparisons test. See also .
    Peptide Ab190844, supplied by Abcam, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ab91335/Human+Growth+Hormone+ELISA+Kit/pmc04180273-100-15-20
    Average 99 stars, based on 1 article reviews
    peptide ab190844 - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    Image Search Results


    Journal: iScience

    Article Title: CD82 expression marks the endothelium to hematopoietic transition at the onset of blood specification in human

    doi: 10.1016/j.isci.2023.107583

    Figure Lengend Snippet:

    Article Snippet: Hoechst 33258 (1/100) (1/100) , Abcam , Ab228550.

    Techniques: Recombinant, Derivative Assay, Cell Culture, Flow Cytometry

    TGFBR1 and BMPR2 are the main effector targets of miR-30-3p in HNSCC. ( a ) Predicted interaction between target proteins was analyzed using STRING database. ( b ) Heatmap representing predicted target gene expression was determined by RT-qPCR in HNSCC cell lines ( n = 4–7). ( c ) Western blot analysis of CAL27, CAL33, and SCC9 cell lines overexpressing miR-30a-3p or miR-30e-3p (c for miR-ctrl, a for miR-30a-3p and e for miR-30e-3p, n = 3–12, * p < 0.05, ** p < 0.01 and *** p < 0.001). ( d ) Immunofluorescence analysis by confocal microscopy of HNSCC cell lines overexpressing miR-30a-3p or miR-30e-3p ( n = 3–4). ( e ) Predicted pairing region between miR-30a-3p or miR-30e-3p and TGFBR1 (position 812–818) and BMPR2 (position 1411–1417). ( f ) Evasion of CAL27, CAL33, and SCC9 cell lines with TGF-β or BMP inhibitors ( n = 16–49 spheroids, * p < 0.05, ** p < 0.01 and *** p < 0.001). ( g ) Survival fraction of CAL27, CAL33, and SCC9 cell lines with TGF-β or BMP inhibitors ( n = 9–12, * p < 0.05 and *** p < 0.001).

    Journal: International Journal of Molecular Sciences

    Article Title: Tumor-Suppressive and Immunomodulating Activity of miR-30a-3p and miR-30e-3p in HNSCC Cells and Tumoroids

    doi: 10.3390/ijms241311178

    Figure Lengend Snippet: TGFBR1 and BMPR2 are the main effector targets of miR-30-3p in HNSCC. ( a ) Predicted interaction between target proteins was analyzed using STRING database. ( b ) Heatmap representing predicted target gene expression was determined by RT-qPCR in HNSCC cell lines ( n = 4–7). ( c ) Western blot analysis of CAL27, CAL33, and SCC9 cell lines overexpressing miR-30a-3p or miR-30e-3p (c for miR-ctrl, a for miR-30a-3p and e for miR-30e-3p, n = 3–12, * p < 0.05, ** p < 0.01 and *** p < 0.001). ( d ) Immunofluorescence analysis by confocal microscopy of HNSCC cell lines overexpressing miR-30a-3p or miR-30e-3p ( n = 3–4). ( e ) Predicted pairing region between miR-30a-3p or miR-30e-3p and TGFBR1 (position 812–818) and BMPR2 (position 1411–1417). ( f ) Evasion of CAL27, CAL33, and SCC9 cell lines with TGF-β or BMP inhibitors ( n = 16–49 spheroids, * p < 0.05, ** p < 0.01 and *** p < 0.001). ( g ) Survival fraction of CAL27, CAL33, and SCC9 cell lines with TGF-β or BMP inhibitors ( n = 9–12, * p < 0.05 and *** p < 0.001).

    Article Snippet: Samples were blocked in PBS/5% BSA/0.3% Triton X-100 for 1 h and incubated overnight at 4 °C with TGFBR1 (ab235178, 1/100, Abcam) or BMPR2 (ab130206, 1/100, Abcam).

    Techniques: Targeted Gene Expression, Quantitative RT-PCR, Western Blot, Immunofluorescence, Confocal Microscopy

    Overexpression of miR-30-3p slows down HNSCC patient-derived tumoroid growth and development. ( a ) Immunohistochemical staining of Keratin 34BE12, p40, p63, and hematoxylin and eosin staining in tumoroid versus the original tumor. ( b ) miR-30a-3p and miR-30e-3p expression was determined by RT-qPCR in tumoroids ( n = 5, *** p < 0.001). ( c ) miR-30a-3p and miR-30e-3p expression was determined by RT-qPCR in tumoroids post-transfection ( n = 4–5, * p < 0.05) ( d ) Number of tumoroids remaining at day 6 post-transfection with mir-30a-3p or miR-30e-3p ( n = 10–20 tumoroids, *** p < 0.001). ( e ) Volume of tumoroids at day 6 transfected with miR-30a-3p or miR-30e-3p. Estimated volume = (4/3) × π (d1/2 × d2/2 × d3/3) ( n = 10–20 tumoroids, * p < 0.05 and ** p < 0.01). ( f ) TGFBR1 and BMPR2 expressions were determined by RT-qPCR in tumoroids ( n = 4–6, ** p < 0.01 and *** p < 0.001). ( g ) BMPR2 expressions were determined by immunostaining in tumoroids ( n = 3).

    Journal: International Journal of Molecular Sciences

    Article Title: Tumor-Suppressive and Immunomodulating Activity of miR-30a-3p and miR-30e-3p in HNSCC Cells and Tumoroids

    doi: 10.3390/ijms241311178

    Figure Lengend Snippet: Overexpression of miR-30-3p slows down HNSCC patient-derived tumoroid growth and development. ( a ) Immunohistochemical staining of Keratin 34BE12, p40, p63, and hematoxylin and eosin staining in tumoroid versus the original tumor. ( b ) miR-30a-3p and miR-30e-3p expression was determined by RT-qPCR in tumoroids ( n = 5, *** p < 0.001). ( c ) miR-30a-3p and miR-30e-3p expression was determined by RT-qPCR in tumoroids post-transfection ( n = 4–5, * p < 0.05) ( d ) Number of tumoroids remaining at day 6 post-transfection with mir-30a-3p or miR-30e-3p ( n = 10–20 tumoroids, *** p < 0.001). ( e ) Volume of tumoroids at day 6 transfected with miR-30a-3p or miR-30e-3p. Estimated volume = (4/3) × π (d1/2 × d2/2 × d3/3) ( n = 10–20 tumoroids, * p < 0.05 and ** p < 0.01). ( f ) TGFBR1 and BMPR2 expressions were determined by RT-qPCR in tumoroids ( n = 4–6, ** p < 0.01 and *** p < 0.001). ( g ) BMPR2 expressions were determined by immunostaining in tumoroids ( n = 3).

    Article Snippet: Samples were blocked in PBS/5% BSA/0.3% Triton X-100 for 1 h and incubated overnight at 4 °C with TGFBR1 (ab235178, 1/100, Abcam) or BMPR2 (ab130206, 1/100, Abcam).

    Techniques: Over Expression, Derivative Assay, Immunohistochemical staining, Staining, Expressing, Quantitative RT-PCR, Transfection, Immunostaining

    miR-30a-3p and miR-30e-3p influence macrophages’ immune response to HNSCC cells. ( a ) Images of M0-polarized THP-1 exposed to CAL27, CAL33, SCC9 overexpressing miR-30a-3p and miR-30e-3p conditioned media in phase-contrast microscopy (×10). ( b ) Western blot analysis of CD86 in M0-polarized THP-1 exposed to CAL27, CAL33, and SCC9 overexpressing miR-30a-3p and miR-30e-3p conditioned media ( n = 7–10, * p < 0.05, ** p < 0.01, *** p < 0.001). ( c ) TGFBR1 expression was determined by RT-qPCR in M0-polarized THP-1 exposed to CAL27, CAL33, SCC9 overexpressing miR-30a-3p and miR-30e-3p conditioned media ( n = 3–4, * p < 0.05, ** p < 0.01, *** p < 0.001). ( d ) Western blot analysis of CD163 in M0-polarized THP-1 exposed to CAL27, CAL33, and SCC9 overexpressing miR-30a-3p and miR-30e-3p conditioned media ( n = 8–10, * p < 0.05, ** p < 0.01, *** p < 0.001). ( e ) Images of MO-polarized THP-1 cells (green) phagocytosing miR-30a-3p or miR-30e-3p-transfected HNSCC cells (red) in confocal microscopy 20× and 63×. ( f ) Percentage of phagocytosis, calculated as the number of M0-polarized THP-1 cells phagocytosing transfected HNSCC cells/total number of M0-polarized THP-1 × 100 ( n = 3–4, * p < 0.05, ** p < 0.01, *** p < 0.001). ( g ) Percentage of phagocytosis with antibody antiCD47, calculated as the number of M0-polarized THP-1 cells phagocytosing transfected HNSCC cells/total number of M0-polarized THP-1 × 100 ( n = 10–18, * p < 0.05).

    Journal: International Journal of Molecular Sciences

    Article Title: Tumor-Suppressive and Immunomodulating Activity of miR-30a-3p and miR-30e-3p in HNSCC Cells and Tumoroids

    doi: 10.3390/ijms241311178

    Figure Lengend Snippet: miR-30a-3p and miR-30e-3p influence macrophages’ immune response to HNSCC cells. ( a ) Images of M0-polarized THP-1 exposed to CAL27, CAL33, SCC9 overexpressing miR-30a-3p and miR-30e-3p conditioned media in phase-contrast microscopy (×10). ( b ) Western blot analysis of CD86 in M0-polarized THP-1 exposed to CAL27, CAL33, and SCC9 overexpressing miR-30a-3p and miR-30e-3p conditioned media ( n = 7–10, * p < 0.05, ** p < 0.01, *** p < 0.001). ( c ) TGFBR1 expression was determined by RT-qPCR in M0-polarized THP-1 exposed to CAL27, CAL33, SCC9 overexpressing miR-30a-3p and miR-30e-3p conditioned media ( n = 3–4, * p < 0.05, ** p < 0.01, *** p < 0.001). ( d ) Western blot analysis of CD163 in M0-polarized THP-1 exposed to CAL27, CAL33, and SCC9 overexpressing miR-30a-3p and miR-30e-3p conditioned media ( n = 8–10, * p < 0.05, ** p < 0.01, *** p < 0.001). ( e ) Images of MO-polarized THP-1 cells (green) phagocytosing miR-30a-3p or miR-30e-3p-transfected HNSCC cells (red) in confocal microscopy 20× and 63×. ( f ) Percentage of phagocytosis, calculated as the number of M0-polarized THP-1 cells phagocytosing transfected HNSCC cells/total number of M0-polarized THP-1 × 100 ( n = 3–4, * p < 0.05, ** p < 0.01, *** p < 0.001). ( g ) Percentage of phagocytosis with antibody antiCD47, calculated as the number of M0-polarized THP-1 cells phagocytosing transfected HNSCC cells/total number of M0-polarized THP-1 × 100 ( n = 10–18, * p < 0.05).

    Article Snippet: Samples were blocked in PBS/5% BSA/0.3% Triton X-100 for 1 h and incubated overnight at 4 °C with TGFBR1 (ab235178, 1/100, Abcam) or BMPR2 (ab130206, 1/100, Abcam).

    Techniques: Microscopy, Western Blot, Expressing, Quantitative RT-PCR, Transfection, Confocal Microscopy

    (A) Kaplan-Meier survival plots of TNBC breast cancer patients with low or high PFKFB4 signature score in TCGA (n = 149) and GEO: GSE21653 (n = 85) database. Medium cut point of PFKFB4 signature score was used to stratified patients. p values were calculated by log rank test. (B) Relative mRNA expression of PFKFB4 in primary tumors and matching metastases in breast cancer patients from GEO: GSE110590 database. p values were calculated by one-way ANOVA and paired t test, two tailed. (C) Immunoblot analyses of PFKFB4 protein expression in LM3.3 human breast cancer cells stably expressing doxycycline inducible non-targeting shRNA (dox-shNT) or two shRNAs targeting PFKFB4 (dox-shPFKFB4 #97 and #99) with or without doxycycline treatment (2 μg/mL). β-actin was used as a loading control. (D) Schematic overview depicting LM3.3 spontaneous metastatic breast cancer model with doxycycline treatment schedule (n = 10). (E) The weight of resected primary tumors (n = 10). Error bars are presented as mean ± SD. ns, not significant, calculated by one-way ANOVA with Dunnett’s multiple comparisons test. (F) Immunoblot analyses of PFKFB4 expression in surgically resected LM3.3 primary tumors after 7 days of doxycycline treatment. Three animal bearing tumors (n = 3) from each group were used for analysis. (G) Representative IVIS image of systemic metastases from each group at day 26 after primary tumor implantation. (H) The kinetics of systemic metastases development after primary tumors were resected, as measured by IVIS imaging (n = 10). Error bars are presented as mean ± SEM. ***p < 0.001 by two-way ANOVA with Dunnett’s multiple comparisons test. See also .

    Journal: Cell reports

    Article Title: Hypoxic activation of PFKFB4 in breast tumor microenvironment shapes metabolic and cellular plasticity to accentuate metastatic competence

    doi: 10.1016/j.celrep.2022.111756

    Figure Lengend Snippet: (A) Kaplan-Meier survival plots of TNBC breast cancer patients with low or high PFKFB4 signature score in TCGA (n = 149) and GEO: GSE21653 (n = 85) database. Medium cut point of PFKFB4 signature score was used to stratified patients. p values were calculated by log rank test. (B) Relative mRNA expression of PFKFB4 in primary tumors and matching metastases in breast cancer patients from GEO: GSE110590 database. p values were calculated by one-way ANOVA and paired t test, two tailed. (C) Immunoblot analyses of PFKFB4 protein expression in LM3.3 human breast cancer cells stably expressing doxycycline inducible non-targeting shRNA (dox-shNT) or two shRNAs targeting PFKFB4 (dox-shPFKFB4 #97 and #99) with or without doxycycline treatment (2 μg/mL). β-actin was used as a loading control. (D) Schematic overview depicting LM3.3 spontaneous metastatic breast cancer model with doxycycline treatment schedule (n = 10). (E) The weight of resected primary tumors (n = 10). Error bars are presented as mean ± SD. ns, not significant, calculated by one-way ANOVA with Dunnett’s multiple comparisons test. (F) Immunoblot analyses of PFKFB4 expression in surgically resected LM3.3 primary tumors after 7 days of doxycycline treatment. Three animal bearing tumors (n = 3) from each group were used for analysis. (G) Representative IVIS image of systemic metastases from each group at day 26 after primary tumor implantation. (H) The kinetics of systemic metastases development after primary tumors were resected, as measured by IVIS imaging (n = 10). Error bars are presented as mean ± SEM. ***p < 0.001 by two-way ANOVA with Dunnett’s multiple comparisons test. See also .

    Article Snippet: PFKFB4 Antibody (Abcam, Cat. No. ab137785) at 1/100 was used for staining.

    Techniques: Expressing, Two Tailed Test, Western Blot, Stable Transfection, shRNA, Tumor Implantation, Imaging

    (A) Gene sets enriched in WT or PFKFB4-KO EMT6 cells identified in RNA-seq data. Top five gene sets significantly enriched in WT cells are listed. Plot showing gene set enrichment analysis (GSEA) of αvβ3 integrin pathway in EMT6 cells. (B) Heatmap showing differentially expressed genes (DEGs) (p < 0.05, Log 2 FC < −1.5 or > 1.5) in αvβ3 integrin pathway. (C) The mRNA expression of ITGB1, ITGB3 (encoding integrin β3), ITGB5, and ITGAV in EMT6 WT and PFKFB4-KO cells measured by quantitative PCR (n = 3). Error bars are presented as mean ± SD. ****p < 0.0001 by one-way ANOVA with Dunnett’s multiple comparisons test. (D) The protein expression of integrin β3 and PFKFB4 in EMT6 WT and PFKFB4-KO cells measured by immunoblotting. β-actin was used as a loading control. (E) Boyden chamber migration assay using EMT6 WT and PFKFB4-KO cells with serum as chemoattractant (n = 3). Scale bar, 300 μm. Error bars are presented as mean ± SD. ****p < 0.0001 by one-way ANOVA with Dunnett’s multiple comparisons test. (F) Boyden chamber migration assay using EMT6 WT and PFKFB4-KO cells using fibronectin (FN; 10 μg/mL) and vitronectin (VN; 5 μg/mL) as chemoattractant. Scale bar, 300 μm. (G) Quantification of FN- and VN-dependent migration (n = 3). Error bars are presented as mean ± SD. **p < 0.01 by unpaired two-tailed t test. (H) Representative immunohistochemistry images showing integrin β3 (red) expression in shNT and shPFKFB4 metastatic lymph nodes from LM3.3 mouse experiments described in . Human HLA (green) was used as a marker for human tumor cells. Scale bar, 50 μm. (I) Quantification of integrin β3 expression in human HLA-positive cells (n = 3). Error bars are presented as mean ± SD. *p < 0.05 by unpaired two-tailed t test. See also and .

    Journal: Cell reports

    Article Title: Hypoxic activation of PFKFB4 in breast tumor microenvironment shapes metabolic and cellular plasticity to accentuate metastatic competence

    doi: 10.1016/j.celrep.2022.111756

    Figure Lengend Snippet: (A) Gene sets enriched in WT or PFKFB4-KO EMT6 cells identified in RNA-seq data. Top five gene sets significantly enriched in WT cells are listed. Plot showing gene set enrichment analysis (GSEA) of αvβ3 integrin pathway in EMT6 cells. (B) Heatmap showing differentially expressed genes (DEGs) (p < 0.05, Log 2 FC < −1.5 or > 1.5) in αvβ3 integrin pathway. (C) The mRNA expression of ITGB1, ITGB3 (encoding integrin β3), ITGB5, and ITGAV in EMT6 WT and PFKFB4-KO cells measured by quantitative PCR (n = 3). Error bars are presented as mean ± SD. ****p < 0.0001 by one-way ANOVA with Dunnett’s multiple comparisons test. (D) The protein expression of integrin β3 and PFKFB4 in EMT6 WT and PFKFB4-KO cells measured by immunoblotting. β-actin was used as a loading control. (E) Boyden chamber migration assay using EMT6 WT and PFKFB4-KO cells with serum as chemoattractant (n = 3). Scale bar, 300 μm. Error bars are presented as mean ± SD. ****p < 0.0001 by one-way ANOVA with Dunnett’s multiple comparisons test. (F) Boyden chamber migration assay using EMT6 WT and PFKFB4-KO cells using fibronectin (FN; 10 μg/mL) and vitronectin (VN; 5 μg/mL) as chemoattractant. Scale bar, 300 μm. (G) Quantification of FN- and VN-dependent migration (n = 3). Error bars are presented as mean ± SD. **p < 0.01 by unpaired two-tailed t test. (H) Representative immunohistochemistry images showing integrin β3 (red) expression in shNT and shPFKFB4 metastatic lymph nodes from LM3.3 mouse experiments described in . Human HLA (green) was used as a marker for human tumor cells. Scale bar, 50 μm. (I) Quantification of integrin β3 expression in human HLA-positive cells (n = 3). Error bars are presented as mean ± SD. *p < 0.05 by unpaired two-tailed t test. See also and .

    Article Snippet: PFKFB4 Antibody (Abcam, Cat. No. ab137785) at 1/100 was used for staining.

    Techniques: RNA Sequencing Assay, Expressing, Real-time Polymerase Chain Reaction, Western Blot, Migration, Two Tailed Test, Immunohistochemistry, Marker

    (A) Quantitative PCR showing the relative levels of PFKFB4 in MDA-MB-468, MDA-MB-231, and EMT6 cells cultured in normoxia (21% O 2 ) or hypoxia (1% O 2 ) (n = 3). Error bars are presented as mean ± SD. **p < 0.01; ***p < 0.001 by unpaired two-tailed t test. (B) Wound healing assay using EMT6 WT and PFKFB4-KO cells cultured in normoxic (21% O 2 ) or hypoxic condition (1% O 2 ) (n = 3). Error bars are presented as mean ± SD. *p < 0.05; ****p < 0.0001; ns, not significant, calculated by one-way ANOVA with Sidak’s multiple comparisons test. (C) The mRNA expression of ITGB3 in EMT6 WT and PFKFB4-KO cells under normoxic (21% O 2 ) or hypoxic condition (1% O 2 ) (n = 3). Error bars are presented as mean ± SD. *p < 0.05; ****p < 0.0001 by one-way ANOVA with Sidak’s multiple comparisons test. (D and E) Immunoblot analyses of integrin β3, HIF-1α, PFKFB4, and β-actin in WT and PFKFB4-KO MDA-MB-468 (D) and EMT6 cells (E) cultured in normoxia (21% O 2 ) or hypoxia (1% O 2 ). (F) Immunoblot analyses showing the levels of endogenous integrin β3 and GFP-integrin β3 along with PFKFB4. β-actin was used as a loading control. (G) Boyden chamber migration assay using EMT6 WT, PFKFB4-KO, and PFKFB4-KO cells with ectopic GFP-integrin β3 cultured in hypoxic condition (1% O 2 ). Scale bar, 300 μm. (H) Quantification of migration assay under hypoxic condition (n = 3). Error bars are presented as mean ± SD. ***p < 0.001 by one-way ANOVA with Dunnett’s multiple comparisons test. See also .

    Journal: Cell reports

    Article Title: Hypoxic activation of PFKFB4 in breast tumor microenvironment shapes metabolic and cellular plasticity to accentuate metastatic competence

    doi: 10.1016/j.celrep.2022.111756

    Figure Lengend Snippet: (A) Quantitative PCR showing the relative levels of PFKFB4 in MDA-MB-468, MDA-MB-231, and EMT6 cells cultured in normoxia (21% O 2 ) or hypoxia (1% O 2 ) (n = 3). Error bars are presented as mean ± SD. **p < 0.01; ***p < 0.001 by unpaired two-tailed t test. (B) Wound healing assay using EMT6 WT and PFKFB4-KO cells cultured in normoxic (21% O 2 ) or hypoxic condition (1% O 2 ) (n = 3). Error bars are presented as mean ± SD. *p < 0.05; ****p < 0.0001; ns, not significant, calculated by one-way ANOVA with Sidak’s multiple comparisons test. (C) The mRNA expression of ITGB3 in EMT6 WT and PFKFB4-KO cells under normoxic (21% O 2 ) or hypoxic condition (1% O 2 ) (n = 3). Error bars are presented as mean ± SD. *p < 0.05; ****p < 0.0001 by one-way ANOVA with Sidak’s multiple comparisons test. (D and E) Immunoblot analyses of integrin β3, HIF-1α, PFKFB4, and β-actin in WT and PFKFB4-KO MDA-MB-468 (D) and EMT6 cells (E) cultured in normoxia (21% O 2 ) or hypoxia (1% O 2 ). (F) Immunoblot analyses showing the levels of endogenous integrin β3 and GFP-integrin β3 along with PFKFB4. β-actin was used as a loading control. (G) Boyden chamber migration assay using EMT6 WT, PFKFB4-KO, and PFKFB4-KO cells with ectopic GFP-integrin β3 cultured in hypoxic condition (1% O 2 ). Scale bar, 300 μm. (H) Quantification of migration assay under hypoxic condition (n = 3). Error bars are presented as mean ± SD. ***p < 0.001 by one-way ANOVA with Dunnett’s multiple comparisons test. See also .

    Article Snippet: PFKFB4 Antibody (Abcam, Cat. No. ab137785) at 1/100 was used for staining.

    Techniques: Real-time Polymerase Chain Reaction, Cell Culture, Two Tailed Test, Wound Healing Assay, Expressing, Western Blot, Migration

    (A) Representative images of ultrasound and photoacoustic imaging (US-PAI) from LM3.3 shNT and shPFKFB4 primary tumors. The images were acquired in 3D-mode and presented in three representative frames showing the oxygen saturation (sO 2 %) from the periphery (left and right frames) and the core (middle frame) of the tumors. (B) Quantification of oxygen saturation (tumor 3D sO 2 %) in shNT and shPFKFB4 tumors (n = 3). Error bars are presented as mean ± SD. ns, not significant, calculated by unpaired two-tailed t test. (C) Immunohistochemical staining of PFKFB4 (red) and pimonidazole (green) from resected LM3.3 shNT and shPFKFB4 primary tumors (n = 4). Pimonidazole isa marker of hypoxia. Each tumor was imaged and quantified in both pimonidazole negative and positive areas. Scale bar, 75 μm. (D) Quantification of the intensity of PFKFB4 staining (n = 4). Error bars are presented as mean ± SD. **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant, calculated by one-way ANOVA with Sidak’s multiple comparisons test. (E) Experimental workflow of in vitro (n = 3) and in vivo (n = 5) targeted metabolomics. (F) Principal component analysis of targeted metabolomics from EMT6 WT and PFKFB4-KO cells cultured in normoxic (21% O 2 ) or hypoxic condition (1% O 2 ). (G) Relative levels of serine, glycine, aspartate, arginine, and GSH/GSSG in WT and PFKFB4-KO EMT6 cells cultured in normoxia (21% O 2 ) or hypoxia (1% O 2 ) (n = 3). Error bars are presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 by one-way ANOVA with Sidak’s multiple comparisons test. (H) Unique metabolic signature regulated by PFKFB4 in TNBC is schematically demonstrated. See also and .

    Journal: Cell reports

    Article Title: Hypoxic activation of PFKFB4 in breast tumor microenvironment shapes metabolic and cellular plasticity to accentuate metastatic competence

    doi: 10.1016/j.celrep.2022.111756

    Figure Lengend Snippet: (A) Representative images of ultrasound and photoacoustic imaging (US-PAI) from LM3.3 shNT and shPFKFB4 primary tumors. The images were acquired in 3D-mode and presented in three representative frames showing the oxygen saturation (sO 2 %) from the periphery (left and right frames) and the core (middle frame) of the tumors. (B) Quantification of oxygen saturation (tumor 3D sO 2 %) in shNT and shPFKFB4 tumors (n = 3). Error bars are presented as mean ± SD. ns, not significant, calculated by unpaired two-tailed t test. (C) Immunohistochemical staining of PFKFB4 (red) and pimonidazole (green) from resected LM3.3 shNT and shPFKFB4 primary tumors (n = 4). Pimonidazole isa marker of hypoxia. Each tumor was imaged and quantified in both pimonidazole negative and positive areas. Scale bar, 75 μm. (D) Quantification of the intensity of PFKFB4 staining (n = 4). Error bars are presented as mean ± SD. **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant, calculated by one-way ANOVA with Sidak’s multiple comparisons test. (E) Experimental workflow of in vitro (n = 3) and in vivo (n = 5) targeted metabolomics. (F) Principal component analysis of targeted metabolomics from EMT6 WT and PFKFB4-KO cells cultured in normoxic (21% O 2 ) or hypoxic condition (1% O 2 ). (G) Relative levels of serine, glycine, aspartate, arginine, and GSH/GSSG in WT and PFKFB4-KO EMT6 cells cultured in normoxia (21% O 2 ) or hypoxia (1% O 2 ) (n = 3). Error bars are presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 by one-way ANOVA with Sidak’s multiple comparisons test. (H) Unique metabolic signature regulated by PFKFB4 in TNBC is schematically demonstrated. See also and .

    Article Snippet: PFKFB4 Antibody (Abcam, Cat. No. ab137785) at 1/100 was used for staining.

    Techniques: Imaging, Two Tailed Test, Immunohistochemical staining, Staining, Marker, In Vitro, In Vivo, Cell Culture

    (A and B) Representative PFKFB4 immunohistochemical staining of breast cancer patients (n = 122) with high or low staining of PFKFB4 in the nucleus (A) and cytoplasm (B). Scale bar, 300 μm. (C and D) Kaplan-Meier analysis of the overall survival of breast cancer patients (n = 122) with high or low expression of PFKFB4 in the nucleus (C) or cytoplasm (D). (E) WT and PFKFB4-KO MDA-MB-468 cells cultured in normoxic (21% O 2 ) or hypoxic condition (1% O 2 ) were subjected to subcellular fractionation, followed by immunoblot analyses of PFKFB4, β-tubulin, and lamin A/C. PFKFB4 blot was imaged for 30 s to obtain a low exposure and 120 s to obtain a high exposure. (F) Immunoblot analyses of nuclear fractions from MDA-MB-468 WT and PFKFB4-KO cells cultured in normoxic or hypoxic conditions were probed with PFKFB4, lamin A/C, and HIF-1α antibodies. (G) MDA-MB-468 cells cultured in normoxic or hypoxic conditions were used for immunofluorescence staining of PFKFB4. Scale bar, 25 μm (low-magnification image) and 10 μm (high-magnification image). (H and I) The mRNA expression of SLC2A1 (H) and PDK1 (I) in WT and PFKFB4-KO MDA-MB-468 cells under normoxic (21% O 2 ) or hypoxic condition (1% O 2 ) was measured by quantitative PCR (n = 3). Error bars are presented as mean ± SD. *p < 0.05; ***p < 0.001; ****p < 0.0001 by one-way ANOVA with Sidak’s multiple comparisons test. (J) HIF-1α luciferase (HRE) reporter assay in MDA-MB-468 WT and PFKFB4-KO cells expressing shNT or shSRC-3 cultured in normoxic (21% O 2 ) or hypoxic condition (1% O 2 ) for 24 h. Error bars are presented as mean ± SD. ****p < 0.0001; ns, not significant, calculated by one-way ANOVA with Sidak’s multiple comparisons test. (K) Immunoblot analyses of SRC-3 and integrin β3 in MDA-MB-231 cells stably expressing shNT or shSRC-3. β-actin was used as a loading control. See also and and .

    Journal: Cell reports

    Article Title: Hypoxic activation of PFKFB4 in breast tumor microenvironment shapes metabolic and cellular plasticity to accentuate metastatic competence

    doi: 10.1016/j.celrep.2022.111756

    Figure Lengend Snippet: (A and B) Representative PFKFB4 immunohistochemical staining of breast cancer patients (n = 122) with high or low staining of PFKFB4 in the nucleus (A) and cytoplasm (B). Scale bar, 300 μm. (C and D) Kaplan-Meier analysis of the overall survival of breast cancer patients (n = 122) with high or low expression of PFKFB4 in the nucleus (C) or cytoplasm (D). (E) WT and PFKFB4-KO MDA-MB-468 cells cultured in normoxic (21% O 2 ) or hypoxic condition (1% O 2 ) were subjected to subcellular fractionation, followed by immunoblot analyses of PFKFB4, β-tubulin, and lamin A/C. PFKFB4 blot was imaged for 30 s to obtain a low exposure and 120 s to obtain a high exposure. (F) Immunoblot analyses of nuclear fractions from MDA-MB-468 WT and PFKFB4-KO cells cultured in normoxic or hypoxic conditions were probed with PFKFB4, lamin A/C, and HIF-1α antibodies. (G) MDA-MB-468 cells cultured in normoxic or hypoxic conditions were used for immunofluorescence staining of PFKFB4. Scale bar, 25 μm (low-magnification image) and 10 μm (high-magnification image). (H and I) The mRNA expression of SLC2A1 (H) and PDK1 (I) in WT and PFKFB4-KO MDA-MB-468 cells under normoxic (21% O 2 ) or hypoxic condition (1% O 2 ) was measured by quantitative PCR (n = 3). Error bars are presented as mean ± SD. *p < 0.05; ***p < 0.001; ****p < 0.0001 by one-way ANOVA with Sidak’s multiple comparisons test. (J) HIF-1α luciferase (HRE) reporter assay in MDA-MB-468 WT and PFKFB4-KO cells expressing shNT or shSRC-3 cultured in normoxic (21% O 2 ) or hypoxic condition (1% O 2 ) for 24 h. Error bars are presented as mean ± SD. ****p < 0.0001; ns, not significant, calculated by one-way ANOVA with Sidak’s multiple comparisons test. (K) Immunoblot analyses of SRC-3 and integrin β3 in MDA-MB-231 cells stably expressing shNT or shSRC-3. β-actin was used as a loading control. See also and and .

    Article Snippet: PFKFB4 Antibody (Abcam, Cat. No. ab137785) at 1/100 was used for staining.

    Techniques: Immunohistochemical staining, Staining, Expressing, Cell Culture, Fractionation, Western Blot, Immunofluorescence, Real-time Polymerase Chain Reaction, Luciferase, Reporter Assay, Stable Transfection

    KEY RESOURCES TABLE

    Journal: Cell reports

    Article Title: Hypoxic activation of PFKFB4 in breast tumor microenvironment shapes metabolic and cellular plasticity to accentuate metastatic competence

    doi: 10.1016/j.celrep.2022.111756

    Figure Lengend Snippet: KEY RESOURCES TABLE

    Article Snippet: PFKFB4 Antibody (Abcam, Cat. No. ab137785) at 1/100 was used for staining.

    Techniques: Cell Culture, Produced, Recombinant, Infection, Western Blot, Lysis, Protease Inhibitor, Bicinchoninic Acid Protein Assay, Plasmid Preparation, Blocking Assay, Stripping, Magnetic Beads, SYBR Green Assay, Luciferase, Amplification, Sequencing, shRNA, Software, Real-time Polymerase Chain Reaction